Mineralys Therapeutics, Inc. Common Stock (MLYS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mineralys Therapeutics, Inc. Common Stock (MLYS) has a cash flow conversion efficiency ratio of -0.062x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-39.47 Million) by net assets ($638.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mineralys Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Mineralys Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Mineralys Therapeutics, Inc. Common Stoc balance sheet liabilities for a breakdown of total debt and financial obligations.
Mineralys Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mineralys Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Greatek Electronics Inc
TW:2441
|
0.062x |
|
Fastly, Inc. Class A Common Stock
NYSE:FSLY
|
0.024x |
|
Ardagh Metal Packaging SA
NYSE:AMBP
|
-0.542x |
|
TMC the metals company Inc
NASDAQ:TMC
|
0.340x |
|
First Bancorp
NASDAQ:FBNC
|
0.033x |
|
China Railway Materials Co Ltd
SHE:000927
|
-0.069x |
|
EMEIS SA
PA:EMEIS
|
0.037x |
|
Elite Advanced Laser Corp
TW:3450
|
0.078x |
Annual Cash Flow Conversion Efficiency for Mineralys Therapeutics, Inc. Common Stock (2020–2025)
The table below shows the annual cash flow conversion efficiency of Mineralys Therapeutics, Inc. Common Stock from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see Mineralys Therapeutics, Inc. Common Stoc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $646.69 Million | $-142.42 Million | -0.220x | +74.68% |
| 2024-12-31 | $191.26 Million | $-166.31 Million | -0.870x | -158.34% |
| 2023-12-31 | $241.15 Million | $-81.17 Million | -0.337x | -160.21% |
| 2022-12-31 | $-52.27 Million | $-29.22 Million | 0.559x | -11.97% |
| 2021-12-31 | $-22.93 Million | $-14.56 Million | 0.635x | -7.25% |
| 2020-12-31 | $-3.60 Million | $-2.46 Million | 0.685x | -- |
About Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, an… Read more